Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vasudevan A Raghavan

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Heart Failure Clinics|September 25, 2012
Insulin resistance and atherosclerosisVasudevan A Raghavan
American Family Physician|March 11, 2008
First-line therapies for lowering triglyceride levelsVasudevan A Raghavan
Heart Failure Clinics|September 25, 2012
Glucolipotoxicity and the heartPeter P Toth, Vasudevan A Raghavan
Current Atherosclerosis Reports|July 24, 2010
Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trialsPatrick Murray, Gary W Chune, Vasudevan A Raghavan
Heart (British Cardiac Society)|April 29, 2010
The enigma of glucose and cardiovascular diseaseCyrus Desouza, Vasudevan A Raghavan, Vivian A Fonseca
Heart Failure Clinics|September 25, 2012
Biochemical basis and clinical consequences of glucolipotoxicity: a primerVellore A R Srinivasan, Vasudevan A Raghavan, Sampath Parthasarathy
Diabetes Care|October 2, 2009
Statin-induced diabetes: will it change clinical practice?L Maria Belalcazar, Vasudevan A Raghavan, Christie M Ballantyne
American Journal of Clinical Oncology|March 22, 2012
Objective measures of physical functional capacity warrant exploration to complement or replace the subjective physician estimated performance statusGuru Sonpavde, Nicholas J Vogelzang, Matthew D Galsky, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Heart Failure Clinics|September 25, 2012
Insulin resistance and atherosclerosisVasudevan A Raghavan
American Family Physician|March 11, 2008
First-line therapies for lowering triglyceride levelsVasudevan A Raghavan
Heart Failure Clinics|September 25, 2012
Glucolipotoxicity and the heartPeter P Toth, Vasudevan A Raghavan
Current Atherosclerosis Reports|July 24, 2010
Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trialsPatrick Murray, Gary W Chune, Vasudevan A Raghavan
Heart (British Cardiac Society)|April 29, 2010
The enigma of glucose and cardiovascular diseaseCyrus Desouza, Vasudevan A Raghavan, Vivian A Fonseca
Heart Failure Clinics|September 25, 2012
Biochemical basis and clinical consequences of glucolipotoxicity: a primerVellore A R Srinivasan, Vasudevan A Raghavan, Sampath Parthasarathy
Diabetes Care|October 2, 2009
Statin-induced diabetes: will it change clinical practice?L Maria Belalcazar, Vasudevan A Raghavan, Christie M Ballantyne
American Journal of Clinical Oncology|March 22, 2012
Objective measures of physical functional capacity warrant exploration to complement or replace the subjective physician estimated performance statusGuru Sonpavde, Nicholas J Vogelzang, Matthew D Galsky, et al.
Pageof 1